RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five …
| Métrica | RDHL | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 60.3% | 57.4% | +2.9% |
| Operating Margin | -181.7% | -34.4% | -147.3% |
| Net Margin | -102.8% | -32.5% | -70.3% |
| FCF Margin | -116.6% | -12.6% | -104.0% |
| ROE | — | -39.2% | — |
| ROA | -45.8% | -30.9% | -14.9% |
| Current Ratio | 0.54 | 2.73 | -2.19 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -45.8% | — |
| ✗Flujo de caja operativo positivo | −$9M | −$36M |
| ✗Rentabilidad sobre activos al alza | -45.8% | 103.8% |
| ✗Caja operativa/activos supera al ROA | -51.9% | ROA -45.8% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 0.54 | 0.81 |
| ✗Sin aumentar el nº de acciones | 12,323M | 2,591M |
| ✓Margen bruto al alza | 60.3% | 47.0% |
| ✓Rotación de activos al alza | 0.45 | 0.28 |
| Calidad del negocio | FY24 |
|---|---|
| ✗Margen FCF > 10 % | -116.6% |
| ✓ROCE > 10 % | 349.6% |
| ✗Ventas > 5 %/año (3 años) | -54.6% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 19.9% |
RedHill Biopharma Ltd. cotiza a 0.48 USD y tiene una capitalización bursátil de $4M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud